{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan%2C+Oxaliplatin%2C+Leucovorin%2C+5-FU&page=3", "query": { "intervention": "Irinotecan, Oxaliplatin, Leucovorin, 5-FU", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 179, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan%2C+Oxaliplatin%2C+Leucovorin%2C+5-FU&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan%2C+Oxaliplatin%2C+Leucovorin%2C+5-FU&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T18:53:56.075Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03563248", "title": "Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "SBRT", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2018-08-10", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-10-11T18:53:56.075Z", "location_count": 10, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563248" }, { "nct_id": "NCT05610163", "title": "Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Stage II Rectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Locally Advanced Rectal Adenocarcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Leucovorin calcium", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Long Course Chemoradiotherapy", "type": "RADIATION" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Sigmoidoscopy", "type": "PROCEDURE" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 760, "start_date": "2022-12-08", "completion_date": "2037-07-01", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-11T18:53:56.075Z", "location_count": 679, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05610163" }, { "nct_id": "NCT03977233", "title": "Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma (PDAC)", "Cancer of Pancreas", "Pancreatic Cancer, Adult", "Pancreas Adenocarcinoma", "Pancreatic Neoplasms", "Pancreatic Cancer Non-resectable", "Pancreatic Cancer Resectable" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 45, "start_date": "2019-06-12", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-11T18:53:56.075Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03977233" }, { "nct_id": "NCT04292743", "title": "Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Eryaspase", "type": "BIOLOGICAL" }, { "name": "FOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2020-12-02", "completion_date": "2024-03-04", "has_results": true, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-10-11T18:53:56.075Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04292743" }, { "nct_id": "NCT06586515", "title": "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "LY3962673", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2024-09-12", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-11T18:53:56.075Z", "location_count": 25, "location_summary": "Duarte, California • Santa Monica, California • Denver, Colorado + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06586515" }, { "nct_id": "NCT01726582", "title": "Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (\"Personalized Medicine\")", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Milestone 1: Targeted chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 2: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 3: Targeted chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 3: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 4: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 5: Targeted chemotherapy after surgery", "type": "DRUG" }, { "name": "Milestone 5: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 6: Gemcitabine after surgery", "type": "DRUG" }, { "name": "Milestone 6: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 7: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 8: Targeted chemotherapy after surgery", "type": "DRUG" }, { "name": "Milestone 9: Gemcitabine after surgery", "type": "DRUG" }, { "name": "Milestone 10: No additional therapy after surgery", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2011-11", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-10-11T18:53:56.075Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Milwaukee, Wisconsin", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01726582" }, { "nct_id": "NCT01959139", "title": "S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "PEGPH20", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 126, "start_date": "2014-01-23", "completion_date": "2023-11-09", "has_results": true, "last_update_posted_date": "2024-02-09", "last_synced_at": "2026-10-11T18:53:56.075Z", "location_count": 154, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Auburn, California + 112 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01959139" }, { "nct_id": "NCT01688336", "title": "FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2012-01", "completion_date": "2016-11-22", "has_results": true, "last_update_posted_date": "2017-10-06", "last_synced_at": "2026-10-11T18:53:56.075Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01688336" }, { "nct_id": "NCT03861702", "title": "Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Pancreatic Carcinoma(LAPC)" ], "interventions": [ { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "Liposomal Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nelson Yee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-09-02", "completion_date": "2024-09-27", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-10-11T18:53:56.075Z", "location_count": 4, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03861702" }, { "nct_id": "NCT03941093", "title": "Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer Non-resectable" ], "interventions": [ { "name": "Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX", "type": "DRUG" }, { "name": "Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 284, "start_date": "2019-05-10", "completion_date": "2024-06-11", "has_results": true, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-10-11T18:53:56.075Z", "location_count": 32, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03941093" } ] }